ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Safety

Oversight Of Dietary Supplements Faulted

by Britt E. Erickson
March 9, 2009 | APPEARED IN VOLUME 87, ISSUE 10

FDA should ask Congress for more authority to oversee dietary supplements, concludes a Government Accountability Office report. In particular, GAO found that FDA has a limited ability to identify concerns related to the safety of dietary supplements because the agency lacks information on how many companies manufacture them and where those companies are located, the types of products currently on the market, and moderate or mild adverse events reported to industry. Manufacturers of dietary supplements are required to report only serious adverse events such as death, hospitalization, or birth defects. When FDA does identify a safety concern, GAO found that FDA is hindered from removing the product from the market because it does not have mandatory recall authority. In addition, GAO found that FDA devotes insufficient resources to oversight of dietary supplements, such as providing guidance to industry on new dietary ingredients and clarifying the boundary between dietary supplements and conventional foods that contain added dietary ingredients.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment